Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
Data from KEYNOTE-590 continue to show durable efficacy after 5 years, and pembrolizumab plus chemotherapy more than tripled the 5-year overall survival rate compared with placebo plus chemotherapy, with no new safety signals. These results support first-line therapy with pembrolizumab plus chemotherapy as standard for previously untreated patients with advanced EC with programmed death-ligand 1 combined positive score ≥1.
Authors
- Pooja Bhagia (ORCID: https://orcid.org/0000-0002-6312-7397)
- Toshihiko Doi (ORCID: https://orcid.org/0000-0003-2042-6829)
- María Alsina (ORCID: https://orcid.org/0000-0003-4835-7159)
- A. Tsuji
- Jimin Wu (ORCID: https://orcid.org/0000-0001-6383-9020)
- Sung‐Bae Kim (ORCID: https://orcid.org/0000-0001-5588-8332)
- Antoine Adenis (ORCID: https://orcid.org/0000-0003-3123-9746)
- J-P. Metges
- Koji Kato (ORCID: https://orcid.org/0000-0001-9846-5903)
- Gary L. Buchschacher (ORCID: https://orcid.org/0009-0000-5713-4155)
- Patrapim Sunpaweravong (ORCID: https://orcid.org/0000-0001-9787-270X)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Lin Shen (ORCID: https://orcid.org/0000-0002-8798-4756)
- Wasat Mansoor
- Hidenori Hara
- Takashi Kojima (ORCID: https://orcid.org/0000-0002-2554-8334)
- Manish A. Shah (ORCID: https://orcid.org/0000-0002-6913-9655)
- Peter C. Enzinger
- Zheng Li (ORCID: https://orcid.org/0000-0002-6141-4990)
- J-M. Sun
- SH Li
- Sukrut Shah
Institutions
- Ulsan College (KR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Prince of Songkla University (TH)
- Chang Gung University (TW)
- Shanghai Jiao Tong University (CN)
- Yonsei University (KR)
- Université de Montpellier (FR)
- Peking University (CN)
- Cornell University (US)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Shanghai Chest Hospital (CN)
- University of Ulsan (KR)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Peking University Cancer Hospital (CN)
- Los Angeles Medical Center (US)
- College Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Saitama Cancer Center (JP)
- Kaiser Permanente West Los Angeles Medical Center (US)
- Vall d'Hebron Hospital Universitari (ES)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- The Christie NHS Foundation Trust (GB)
- Kagawa University Hospital (JP)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- National Cancer Center Hospital East (JP)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105854
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Celgene
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Jazz Pharmaceuticals
- Miyarisan Pharmaceutical
- Nippon Zoki Pharmaceutical
- Mirati Therapeutics
- BeiGene
- Boehringer Ingelheim Japan
- Yuhan
- Coherus Biosciences
- Eisai
- Astellas Pharma
- Shionogi
- Terumo
- Servier
- Yakult Honsha
- Ono Pharmaceutical
- LG Chem
- Novartis Pharma
- Pfizer Japan
- Chugai Pharmaceutical
- MSD K.K.
- Eli Lilly Japan
- Bayer Yakuhin
- Daiichi Sankyo Europe